tbuckley/cabot-search huggingface dataset:
Tiredness in a patient treated with itraconazole
Authors: Preethi Nalla, Thomas Alexander Dacruz, Kofi Obuobie
Journal: BMJ (2017)

A 72 year old woman with allergic bronchopulmonary aspergillosis and asthma presented to the emergency department with a two week history of increasing tiredness and shortness of breath. She had no headache, visual disturbance, abdominal pain, nausea, vomiting, or collapse. Her medication included Seretide 250 Evohaler (fluticasone 250 µg and salmeterol 25 µg) one puff twice daily for four years and inhaled Salbutamol. She had been treated with itraconazole 200 mg daily for two years, after unsuccessful attempts to stop this medication due to recurrence of the disease. She had never required treatment with oral corticosteroids. There was no family history of autoimmune disorders.

Observations were stable on admission, specifically no postural hypotension. General physical examination was unremarkable. There was no hyperpigmentation, visual field defects, or clinical features of Cushing’s syndrome.

Full blood count, serum glucose, renal, and liver function tests were within normal limits. Random serum cortisol (1300 hours) was 4 nmol/L (9 am cortisol range, 138-635). Pituitary profile tests including TSH, FSH, LH, prolactin, and IGF-1 were within normal limits for the patient’s age. Adrenocorticotrophic hormone was less than 10 ng/L (7-51) and adrenal autoantibodies were negative. Chest radiograph and magnetic resonance imaging of pituitary showed no abnormal findings.

### 1. What is the most likely diagnosis based on the hormone profile?

#### Short answer

The hormone profile indicates secondary adrenal insufficiency. This explains the symptoms of tiredness and shortness of breath coupled with a very low serum cortisol (4 mmol/L) and a supressed adrenocorticotrophic hormone level.

#### Discussion

This patient presented with non-specific symptoms and the clinical examination was entirely normal. The random cortisol levels were barely detectable, with suppressed adrenocorticotrophic hormone levels consistent with secondary adrenal insufficiency. The other …
Pretransplant Recipient Blood CD14+ preDC Levels Correlate with Increased Acute GVHD after Allogeneic PBSC Transplantation.
Authors: Mario Arpinati, Panagiota Giannoullia, Gabriella Chirumbolo, Giulia Perrone, Francesca Bonifazi, Yogen Sanuthararajah, Francesca Palandri, Maria Benedetta Giannini, Giuseppe Bandini, Valeria Martelli, Sara Sanchini, Michele Baccarani, Damiano Rondelli
Journal: Blood (2004)
Comparison of High Dose Chemotherapy with Autologous Stem Cell Rescue (ASCT) Versus Consolidation Chemotherapy for Patients &lt; 60 with Cytogenetically Normal AML (CN-AML) and Flt3 ITD
Authors: Harshabad Singh, Lillian Werner, Daniel J DeAngelo, Philip C. Amrein, Martha Wadleigh, Karen K Ballen, Ilene Galinsky, Donna Neuberg, Edward Fox, Richard M Stone, Eyal C Attar
Journal: Blood (2010)
Structural, Functional, and Dynamic Characterization of the Binding Site of RUC-1, a Novel αIIb-Specific Inhibitor of Integrin αIIbβ3.
Authors: Jieqing Zhu, Jianghai Zhu, Ana Negri, Davide Provasi, Marta Filizola, Barry S. Coller, Timothy A Springer
Journal: Blood (2009)
Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
Authors: Edward Gregg, John Jakicic, George Blackburn, Paul Bloomquist, George Bray, Jeanne Clark, Mace Coday, Jeffrey Curtis, Caitlin Egan, Mary Evans, John Foreyt, Gary Foster, Helen Hazuda, James Hill, Edward Horton, Van Hubbard, Robert Jeffery, Karen Johnson, Abbas Kitabchi, William Knowler, Andrea Kriska, Wei Lang, Cora Lewis, Maria Montez, David Nathan, Rebecca Neiberg, Jennifer Patricio, Anne Peters, Xavier Pi-Sunyer, Henry Pownall, Bruce Redmon, Judith Regensteiner, Jack Rejeski, Paul Ribisl, Monika Safford, Kerry Stewart, Dace Trence, Thomas Wadden, Rena Wing, Susan Yanovski
Journal: The Lancet Diabetes & Endocrinology (2016)
Case 3-2017
Authors: Martin A. Samuels, R. Gilberto Gonzalez, Azure T. Makadzange, E. Tessa Hedley-Whyte
Journal: New England Journal of Medicine (2017)

A 62-year-old man with sarcoidosis was admitted to this hospital because of diplopia and weakness. Examination of the CSF revealed elevated opening pressure and leukocytosis. The patient’s condition deteriorated rapidly. He died 10 days later. A diagnosis was made.
Differential Cytokine and Chemokine Profiles from MGUS, SMM, and MM Patient Bone Marrow; Significance of Stromal Interaction and Correlation of IL-8 with the Progression of Myeloma.
Authors: Michael P. Kline, Kathleen A. Donovan, Laurie L. Moon-Tasson, Christopher E. Lust, Wendy Y. Jin, John A. Lust
Journal: Blood (2004)
Association of high cytoplasmic expression of p27 Kip1 on cancer-specific survival in clear cell renal cell carcinoma.
Authors: Jens Bedke, Bastian Amend, Marcus Scharpf, Karl-Dietrich Sievert, Arnulf Stenzl, Stephan Kruck
Journal: Journal of Clinical Oncology (2012)

418 Background: p27Kip1 is considered to contribute to the progression of ccRCC and is targeted by next generation dual-therapies. Cytoplasmic and nuclear differences of p27 Kip1 expression and localization in benign and clear cell renal cell carcinoma (ccRCC) were analyzed with regard to overall survival (OS) and cancer-specific survival (CSS). Methods: In 140 patients, ccRCC and corresponding benign kidney tissue were analyzed for nuclear and cytoplasmic staining of p27Kip1 by immunohistochemistry using a tissue microarray technique. Staining intensity and percentage of positive stained cells are given as expression scores. p27Kip1 expression was categorized as high if ccRCC tissue stained stronger than the respective level of the corresponding benign tissue and categorized as low if ccRCC tissue stained less than or equal to the corresponding benign tissue. Differences in OS and CSS were analyzed by log-rank analysis and expression levels were correlated with tumour and patient characteristics using Fisher’s exact test. Results: Cytoplasmatic (mean [SD]: 13.8% [1.2%] vs 10.7% [1.7%]; P = 0.04) and nuclear (mean [SD]: 75.6% [2.7%] vs 13.6% [2.1%]; P &lt; 0.001) staining of p27Kip1 were significantly stronger in ccRCC tissues compared to benign tissue. High cytoplasmic p27Kip1 expression was significantly associated with a higher T and N stage, Fuhrman grade and the presence of metastatic disease (P &lt; 0.001). The median follow-up time was 38.2 months. There was no difference in OS between the low and high expression groups, although CSS was significantly lower in patients with high cytoplasmic p27Kip1 (P &lt; 0.001) and CSS heavily tended to be lower in the nuclear low expression group (P = 0.069). Conclusions: High cytoplasmic p27Kip1 levels in renal cancer tissues are associated with advanced disease and reduced cancer specific survival, whereas low nuclear expression levels appear to be beneficial. The present study corroborates the consideration of cytoplasmic p27Kip1 for future diagnostic and targeted therapeutic approaches in RCC establishing a potential protective shift of p27Kip1 from the cytoplasm to the nucleus.
Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients.
Authors: Augusto B. Federici, Paolo Bucciarelli, Giancarlo Castaman, Maria G. Mazzucconi, Massimo Morfini, Angiola Rocino, Mario Schiavoni, Francesco Rodeghiero, Pier M. Mannucci
Journal: Blood (2007)
Endoplasmic reticulum stress in the pathogenesis of pretibial dystrophic epidermolysis bullosa
Authors: M. Hattori, A. Shimizu, D. Oikawa, K. Kamei, K. Kaira, A. Ishida-Yamamoto, H. Nakano, D. Sawamura, F. Tokunaga, O. Ishikawa
Journal: British Journal of Dermatology (2017)

Dystrophic epidermolysis bullosa (DEB) is a rare hereditary disease characterized by blistering and scarring of the skin 1 and caused by mutations in the COL7A1 gene which codes type VII collagen (C7). Pretibial dominant dystrophic epidermolysis bullosa (DDEB-Pt) is a subtype of DDEB that predominantly affects the pretibial region.

This article is protected by copyright. All rights reserved.
Histological diagnosis of basal cell carcinoma is not associated with life expectancy in elderly Dutch people: a population-based cohort study
Authors: R. Waalboer-Spuij, L.M. Hollestein, L.V. van de Poll-Franse, T.E.C. Nijsten
Journal: British Journal of Dermatology (2017)

Determining appropriate care at the end of life is challenging and has primarily focused on life threatening diseases. Recently, Linos et al highlighted issues about the management of common, nonfatal conditions such as basal cell carcinoma (BCC) in people with limited life expectancy (LLE).1 A prospective cohort study showed that age older than 85 years or the presence of multiple comorbidities did not influence treatment.2 In two controversial position papers they argued that potential overdiagnosis of an asymptomatic slow growing BCC may do more harm than good, advocating a patient-centred care model.

This article is protected by copyright. All rights reserved.
A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Preliminary Phase 1/2 Study Results in Patients with PNH
Authors: Anita Hill, Anna Gaya Valls, Morag Griffin, Talha Munir, Anna Borodovsky, Nori Kawahata, Helen Mclean, Kelvin Shi, Angela M. Partisano, Jae Kim, Nader Najafian, Alvaro Urbano
Journal: Blood (2016)
Dietary Supplementation with Homoarginine Preserves Cardiac Function in a Murine Model of Post-Myocardial Infarction Heart Failure
Authors: Dorothee Atzler, Debra J. McAndrew, Kathrin Cordts, Jürgen E. Schneider, Sevasti Zervou, Edzard Schwedhelm, Stefan Neubauer, Craig A. Lygate
Journal: Circulation (2017)
Induction of Indoleamine 2,3-Dioxygenase Expression by Interferon-g in Human Mesenchymal Stem Cells Inhibits Graft Versus Host Disease
Authors: Myoung Woo Lee, Dae Seong Kim, Hye Jin Kim, Meong Hi Son, Soo Hyun Lee, Hye Lim Jung, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo
Journal: Blood (2011)
Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group
Authors: Lionel Ades, Xavier Thomas, Agnes Guerci-Bresler, Raffoux Emmanuel, Olivier Spertini, Norbert Vey, Thierry Lamy, Christian Récher, Arnaud Pigneux, Dominique Bordessoule, Eric Deconinck, Claude Gardin, Olivier Tournilhac, Jean-Francois Lambert, Patrice Chevallier, Stephane de Botton, Julie Lejeune, Hervé Dombret, Sylvie Chevret, Pierre Fenaux
Journal: Blood (2015)
Impact of race on prostate cancer selection and cause-specific mortality: A SEER database analysis.
Authors: Catherine Duarte, Natasha Sarkisian, Paul Linh Nguyen, Eva Garroutte, Mark D Hurwitz
Journal: Journal of Clinical Oncology (2012)

248 Background: The objective of this study was to assess relationships between race, treatment, and cause-specific mortality for prostate cancer. Methods: The Surveillance, Epidemiology and End Results (SEER) database yielded 328,151 prostate cancer patients diagnosed between 1990–2007 including 5,129 Japanese-American, 50,717 Black-American, and 282,305 White-American men. Japanese-American men were selected as they have the lowest incidence of prostate cancer and best treatment outcomes. Cox proportional-hazards regression analysis was used to assess association of race with prostate-cancer specific mortality before and after adjusting for age, health, and treatment. To assess impact of race on treatment selection, we compared mean incidence of treatment type [external beam radiation therapy (EBRT), brachytherapy, and surgery] by race using one-way ANOVA and post-testing with Bonferroni correction. Results: Race significantly impacted survival after prostate cancer treatment. Blacks had the highest (HR= 1.198; 95% CI: 1.159 to 1.239, p&lt; .001) and Japanese the lowest (HR= .618; 95% CI: .560 to .682, p&lt; .001) mortality hazard compared to Whites. Tumor grade was the strongest predictor of survival (p&lt; .001). Treatment was also significant: Brachytherapy had the lowest mortality hazard for radiation treatments and surgery was associated with lower mortality hazard compared to no surgery. 37.8%, 44.1%, and 29.1% of Blacks, Whites, and Japanese-Americans underwent surgery (p&lt; .05), 27.3%, 23.8%, and 38.2% of Blacks, Whites, and Japanese-Americans underwent EBRT, (p&lt; .05), and 4.9%, 6.7%, and 4.7% of Blacks, Whites, and Japanese-Americans underwent brachytherapy, with Whites significantly different from the other groups( p&lt;.05). Conclusions: SEER database analysis revealed race impacts prostate cancer survival. Treatment selection for prostate cancer differs among racial groups and race is associated with differential treatment outcomes. Comparisons between treatments must be viewed with caution as confounding variables likely exist not accounted for in the SEER database. Future research on race, treatment, and socioeconomic impact on cancer-specific mortality is warranted.
Endoscopic full-thickness resection for inverted Meckel’s diverticulum using double-balloon enteroscopy
Authors: Kazutoshi Konomatsu, Toshio Kuwai, Toshiki Yamaguchi, Hiroki Imagawa, Atsushi Yamaguchi, Hirotaka Kouno, Hiroshi Kohno
Journal: Endoscopy (2017)

Meckel's diverticulum contains all layers of the small bowel wall and is usually treated by surgery [1] [2]. Inverted Meckel's diverticulum is rare, with only two reports of endoscopic resection [3] [4]. As preoperative diagnosis of an inverted Meckel's diverticulum is difficult [5], it was not diagnosed prior to resection in either case, and consequently perforation due to endoscopic resection was reported in one case [3]. In the current case, we diagnosed the condition preoperatively, and subsequently used two detachable snares prior to resection to prevent hemorrhage or perforation. We then safely treated the inverted Meckel's diverticulum using endoscopic full-thickness resection with double-balloon enteroscopy (DBE).
IL-33/ST2 Triggering of IL-9-Secreting T Cells Alters the Balance of Fatal Immunity and Tumor Immunity
Authors: Abdulraouf Ramadan, Jilu Zhang, Mohammad Abu Zaid, Heather O'Leary, Reuben Kapur, Helmut Hanenberg, Jie Sun, Hal E. Broxmeyer, Mark H. Kaplan, Sophie Paczesny
Journal: Blood (2015)
Long-term mortality in cancer patients with preexisting diabetes-reply
Authors: L.V. van de Poll-Franse, J.W.W. Coebergh
Journal: JAMA (2009)

1. Harder T, Rodekamp E, Schellong K, Dudenhausen JW, Plagemann A. Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am J Epidemiol. 2007; 165(8):849-857. 2. Rich-Edwards JW, Colditz GA, Stampfer MJ, et al. Birthweight and the risk for type 2 diabetes mellitus in adult women. Ann Intern Med. 1999;130(4 pt 1): 278-284. 3. Wei JN, Sung FC, Li CY, et al. Low birth weight and high birth weight infants are both at an increased risk to have type 2 diabetes among schoolchildren in Taiwan. Diabetes Care. 2003;26(2):343-348. 4. Young TK, Martens PJ, Taback SP, et al. Type 2 diabetes mellitus in children: prenatal and early infancy risk factors among native Canadians. Arch Pediatr Adolesc Med. 2002;156(7):651-655.
MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma
Authors: Salomon Manier, John Powers, Antonio Sacco, Siobhan Glavey, Daisy Huynh, Michaela R. Reagan, Karma Salem, Michele Moschetta, Yuji Mishima, Xavier Leleu, Aldo M Roccaro, George Q. Daley, Irene M. Ghobrial
Journal: Blood (2015)
Immune Reconstitution Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: The Impact of Expanding CD28negCD8+ T-Cells on Relapse.
Authors: Ibrahim Yakoub-Agha, Pasquine Saule, Julia Salleron, Pascale Cracco, Valerie Coiteux, Leonardo Magro, Francoise Dufosse, Benedicte Bruno, Jean-Pierre Jouet, Alain Duhamel, Jean-Paul Dessaint, Myriam Labalette
Journal: Blood (2008)
Allosteric Akt Inhibitor MK2206 Synergizes with Bendamustine in Promoting the Apoptosis of Chronic Lymphocytic Leukemia Cells and Selectively Targets B-Cell Receptor Mediated Cytokine Production
Authors: Wei Ding, Tait D. Shanafelt, Connie Lesnick, Traci Sassoon, Charla Secreto, Charles Erlichman, Jose Leis, Timothy G. Call, Deborah Bowen, Shaji K. Kumar, Neil E. Kay
Journal: Blood (2012)
Impact of gamma/delta TCR+, Foxp3+ and Toll-Like Receptor Expressing T-Cells on the Outcome of Patients Receiving Unrelated Peripheral Blood Stem Cell Transplantation.
Authors: Uwe Platzbecker, Caroline Pabst, Holger Schirutschke, Ines Wagner, Cathrin Theuser, Gerhard Ehninger, Martin Bornhauser
Journal: Blood (2006)
Allocation of Internal Medicine Resident Time in a Swiss Hospital: A Time and Motion Study of Day and Evening Shifts
Authors: Nathalie Wenger, Marie Méan, Julien Castioni, Pedro Marques-Vidal, Gérard Waeber, Antoine Garnier
Journal: Annals of Internal Medicine (2017)

Little current evidence documents how internal medicine residents spend their time at work, particularly with regard to the proportions of time spent in direct patient care versus using computers.To describe how residents allocate their time during day and evening hospital shifts.Time and motion study.Internal medicine residency at a university hospital in Switzerland, May to July 2015.36 internal medicine residents with an average of 29 months of postgraduate training.Trained observers recorded the residents' activities using a tablet-based application. Twenty-two activities were categorized as directly related to patients, indirectly related to patients, communication, academic, nonmedical tasks, and transition. In addition, the presence of a patient or colleague and use of a computer or telephone during each activity was recorded.Residents were observed for a total of 696.7 hours. Day shifts lasted 11.6 hours (1.6 hours more than scheduled). During these shifts, activities indirectly related to patients accounted for 52.4% of the time, and activities directly related to patients accounted for 28.0%. Residents spent an average of 1.7 hours with patients, 5.2 hours using computers, and 13 minutes doing both. Time spent using a computer was scattered throughout the day, with the heaviest use after 6:00 p.m.The study involved a small sample from 1 institution.At this Swiss teaching hospital, internal medicine residents spent more time at work than scheduled. Activities indirectly related to patients predominated, and about half the workday was spent using a computer.Information Technology Department and Department of Internal Medicine of Lausanne University Hospital.
Erlotinib-associated rash correlates with plasma levels at steady state
Authors: R. M. Strother, D. R. Jones, T. Skaar, W. S. Huh, J. Porter, A. Foster, C. Sweeney
Journal: Journal of Clinical Oncology (2006)

13008 Background: Erlotinib is a small molecule epidermal growth factor receptor tyrosine kinase inhibitor that is approved for non-small cell lung cancer as a single agent and for pancreatic cancer in combination with gemcitabine. Significant inter-individual variation in drug exposure may explain differential patient outcomes. Genetic polymorphisms of metabolizing enzymes of erlotinib may explain this variability in exposure. Biotransformation assays have implicated cytochrome 3A4/5 (CYP3A4/5) as the predominant metabolizing enzyme. Methods: Patients were enrolled onto a phase-1 dose-escalation study of weekly docetaxel with fixed oral daily dosing (150 mg) of erlotinib. Pharmacodynamic data regarding grade of rash per CTCAE v. 2 were recorded on all 23 patients. Samples for erlotinib pharmacokinetics were obtained after 28 days of continuous daily dosing. Pharmacokinetic (PK) data was attained in 21 patients using LC/MS/MS and analyzed using noncompartmental analysis. Genomic DNA was available for analysis in all 23 patients. Analysis for single nucleotide polymorphisms CYP3A5*3 and CYP2D6*4 were performed by real-time polymerase chain reaction and confirmed by restriction fragment length polymorphism analysis when needed. Results: Average age of patients was 56 (34–76). Nine patients had grade 0–1 rash and 12 had grade 2 rash. As summarized in the table below, the AUC for patients exhibiting grade 2 rash was approximately twice that of patients with grade 0–1 rash. No significant association was found between PK parameters and either CYP3A5 or CYP2D6 polymorphisms. Conclusions: In patients treated with erlotinib the pharmacodynamic endpoint of rash, which has been previously linked with improved patient outcomes, is significantly correlated to the degree of exposure to the drug at steady state. Preliminary data in this small study analyzing pharmacogenetics of erlotinib found no significant correlation between CYP3A5*3 and CYP2D6*4 polymorphic status in either PK or pharmacodynamic measures. [Table: see text] [Table: see text]
Re: Zarubina et al.: Prevalence of subretinal drusenoid deposits in older persons with and without age-related macular degeneration, by multimodal imaging (Ophthalmology 2016;123:1090-1100)
Authors: Thibaud Mathis, Flore De Bats, Martine Mauget-Faÿsse, Philippe Denis, Laurent Kodjikian
Journal: Ophthalmology (2017)
Interim Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).
Authors: Hazem Sayala, Paul Moreton, Jones A. Richard, Rawstron C. Andy, O’Connor Sheila, Evans Paul, Carter Anthony, Dearden Claire, Matutes Estella, Pettitt R. Andrew, Kennedy B. Daniel, Hillmen Peter
Journal: Blood (2005)
Clinical Features and Effects of Eradication on Helicobacter Pylori Positive 207 ITP Cases in Japan.
Authors: Kingo Fujimura, Masataka Kuwana, Yoshiyuki Kurata, Masahiro Imamura, Hiroshi Harada, Hisashi Sakamaki, Masanao Teramura, Kyuhei Koda, Shosaku Nomura, Sayaka Sugihara, Takeshi Shimomura, Tetsuro Takahiro Fujimoto, Kazuma Oyashiki, Yasuo Ikeda
Journal: Blood (2004)
HuMax-CD4 (Zanolimumab), a Fully Human Monoclonal Antibody: Early Results of an Ongoing Clinical Trial in CD4+ Peripheral T-Cell Lymphoma of Non-Cutaneous Type.
Authors: Francesco d’Amore, T. Relander, H. Hagberg, A. Osterborg, M. Hansen, L. Moeller, P. Johnson, J. Radford, B. Hancock, M. Gramatzki, S. Krause, M. Dreyling, N. Schmitz, S. Lisby, O. Baadsgaard
Journal: Blood (2005)
Novel approaches and perspectives in allergen immunotherapy
Authors: H. J. Hoffmann, E. Valovirta, O. Pfaar, P. Moingeon, J. M. Schmid, S. H. Skaarup, L.‐O. Cardell, K. Simonsen, M. Larché, S. R. Durham, P. Sørensen
Journal: Allergy (2017)

Abstract In this review, we report on relevant current topics in allergen immunotherapy ( AIT ) which were broadly discussed during the first Aarhus Immunotherapy Symposium (Aarhus, Denmark) in December 2015 by leading clinicians, scientists and industry representatives in the field. The aim of this symposium was to highlight AIT ‐related aspects of public health, clinical efficacy evaluation, mechanisms, development of new biomarkers and an overview of novel therapeutic approaches. Allergy is a public health issue of high socioeconomic relevance, and development of evidence‐based action plans to address allergy as a public health issue ought to be on national and regional agendas. The underlying mechanisms are in the focus of current research that lays the ground for innovative therapies. Standardization and harmonization of clinical endpoints in AIT trials as well as current knowledge about potential biomarkers have substantiated proof of effectiveness of this disease‐modifying therapeutic option. Novel treatments such as peptide immunotherapy, intralymphatic immunotherapy and use of recombinant allergens herald a new age in which AIT may address treatment of allergy as a public health issue by reaching a large fraction of patients.
Drug Delivery Research for the Future: Expanding the Nano Horizons and Beyond
Authors: Samir Mitragotri, Twan Lammers, You Han Bae, Steven Schwendeman, Stefaan De Smedt, Jean-Christophe Leroux, Dan Peer, Ick Chan Kwon, Hideyoshi Harashima, Akihiko Kikuchi, Yu-Kyoung Oh, Vladmir Torchilin, Wim Hennink, Justin Hanes, Kinam Park
Journal: Journal of Controlled Release (2017)